In summary, this multinational analysis highlights the low proportion of treatment initiation for anemia with existing conventional therapies for advanced NDD-CKD patients, even at levels of Hb and iron parameters that are indications for anemia treatment according to clinical guidelines, and among patients with comorbidity-specific indications for treatment. This evidence concerns the gene GSTM1 and anemia (phenotype).